Advances in data-driven drug discovery are transforming how therapeutic targets are identified and prepared for downstream development.
In this webinar, Axxam and Molecular Health present a best-practice, end-to-end framework for integrating AI-enabled analytics with experimental target validation. We will explore how expertly curated and deeply integrated clinical, omics, and real-world data inform the prioritization of actionable targets, and how these insights transition into structured wet-lab validation workflows.
The webinar will illustrate how combining deep biomedical analytics with biological expertise strengthens early decision-making, reduces risk, and accelerates progress toward therapeutic discovery.
Join the free webinar with certification of attendance now.
Join the Webinar To Learn:
- Current best practices for analytics- and AI-supported target identification
- How Molecular Health’s Dataome supports target selection and builds confidence in early-stage decisions
- How Axxam’s methodologies enable the translation of in silico insights into experimental validation
- How the combined Axxam–Molecular Health capabilities streamline early discovery
This Webinar is Ideal for:
- C-level Executive / President (Pharma & Biotech)
- Director / Head of R&D / R&D Manager (Pharma & Biotech)
- Scientist / Research Investigator (Pharma, Biotech, Academia)
- Professor (Academia)
About the Webinar Speakers
Alessandro Cinti is a Scientific Research Expert at Axxam with over 15 years of experience spanning international academic research and industrial biotech R&D. He currently specializes in drug discovery and early-stage development, with a focus on small molecules, innovative platforms, and translational science. Prior to joining Axxam, Alessandro conducted postdoctoral research at McGill University, focusing on the molecular biology of HIV-1 and host–pathogen interactions in Ebola infection. He holds a PhD in Translational and Molecular Medicine and is the author and co-author of several scientific publications in the field.
Samuel (Sam) Bradberry is a Principal Scientist in the Data Sciences team at Axxam. He supports data and knowledge-driven discovery for Axxam’s clients and the development and management of internal data and knowledge infrastructures. He holds a PhD (2017, Trinity College Dublin) and master’s degree in chemistry (2012, University of Southampton), and has specialized throughout the last decade in management, processing, and interpretation of scientific data in the chemical and life sciences. Sam's current interests are in the close integration of data, knowledge and in-silico methods with wet-lab experimental cycles to enrich the discovery process.
Stephan Brock, PhD, is co-founder and CTO of Molecular Health. He leads the development of AI-driven, knowledge graph–based systems for decision support in pharmaceutical R&D, integrating molecular, clinical, and real-world data into actionable insights. His work spans bioinformatics and systems biology and includes regulatory-grade applications under IVDR, data-driven solutions for the FDA, and the design and implementation of clinical data infrastructure at leading cancer centers. He holds a PhD in Biochemistry from the University of Bayreuth.